Microscopic polyangiitis classification: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Microscopic polyangiitis}} {{CMG}}{{APM}}{{AE}}{{KW}} ==Overview== ==References== {{reflist|2}} {{WH}} {{WS}}")
 
Line 4: Line 4:


==Overview==
==Overview==
According to The International Chapel Hill Consensus Conference (CHCC) criteria based on Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV)
==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Revision as of 19:37, 12 April 2018

Microscopic polyangiitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Microscopic polyangiitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Microscopic polyangiitis classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Microscopic polyangiitis classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Microscopic polyangiitis classification

CDC on Microscopic polyangiitis classification

Microscopic polyangiitis classification in the news

Blogs on Microscopic polyangiitis classification

Directions to Hospitals Treating Type chapter name here

Risk calculators and risk factors for Microscopic polyangiitis classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2]Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3]

Overview

According to The International Chapel Hill Consensus Conference (CHCC) criteria based on Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV)

References

Template:WH Template:WS